Agilent agrees to acquire Proscia in deal worth up to $270 million

Agilent Technologies agreed on October 13, 2026 to acquire digital pathology software maker Proscia for up to $270 million—$240 million cash at closing plus up to $30 million in performance milestones. Proscia's Concentriq platform serves more than 4,000 laboratories, hospitals and clinics and 16 of the top 20 pharmaceutical companies, with more than $18 million in trailing-12-month revenue. After closing, Proscia will join Agilent's Life Sciences and Diagnostics Markets Group. Rated coverage so far is 0 left, 1 center, and 2 right Agilent President and CEO Padraig McDonnell said: "Digital pathology is quickly becoming the foundation for pathology data generation, analysis, and application across biopharmaceutical research, clinical development, and diagnostics, and our acquisition of Proscia meaningfully expands our presence in this fast-growing market." He said the deal establishes an Agilent platform for scientific intelligence in tissue-based precision medicine, connecting data generation with AI-based interpretation. HIT Consultant dates the original commercial distribution partnership to September 2022; FINCHANNEL cites a March 8, 2023 announcement. HIT Consultant put the upfront enterprise value-to-revenue multiple at approximately 13.3x, expanding to 15.0x including earnouts. The deal is expected to close early in Agilent's fiscal 2027.